Core Insights - The report highlights significant changes in the Hong Kong Stock Connect holdings, with notable increases and decreases in ownership percentages for various companies [1][2]. Group 1: Increased Holdings - Shandong Molong (00568) saw the largest increase in ownership percentage, rising by 5.60% to a total holding of 60.72% [2]. - Hang Seng China Enterprises (02828) and InnoCare Pharma-B (09606) also experienced increases of 2.74% and 2.24%, respectively, with holdings of 3.48% and 16.81% [2]. - Over the last five trading days, InnoCare Pharma-B (09606) had the highest increase at 8.96%, followed by Kinglong United Automotive Industry (06680) at 5.81% and Shandong Molong (00568) at 5.37% [1][3]. Group 2: Decreased Holdings - Goldwind Technology (02208) experienced the largest decrease in ownership percentage, dropping by 1.90% to 47.73% [2]. - Other companies with significant decreases include Yangtze Optical Fibre and Cable (06869) and Shanghai Electric (02727), which saw reductions of 1.74% and 1.15%, respectively [2]. - In the last five trading days, Haichang Ocean Park (02255) had the most significant decrease at -5.61%, followed by Yangtze Optical Fibre and Cable (06869) at -5.34% and Goldwind Technology (02208) at -4.01% [1][3]. Group 3: Long-term Trends - Over a 20-day period, Canggang Railway (02169) had the highest increase in ownership percentage at 31.52%, followed by Dazhong Public Utilities (01635) at 30.15% [4]. - Conversely, Haichang Ocean Park (02255) saw a notable decrease of 7.96% in ownership over the same period [4].

Core Insights - The article highlights the changes in the Hong Kong Stock Connect holdings, indicating significant increases and decreases in ownership percentages for various companies [1][2][3]. Summary by Category Increase in Holdings - The companies with the largest increases in Hong Kong Stock Connect holdings include: - Envision Biotech-B (09606) with an increase of 2.57%, bringing the total holding to 14.57% [2]. - Chongqing Steel (01053) with an increase of 1.07%, resulting in a holding of 28.31% [2]. - Yingfu Fund (02800) with an increase of 0.89%, now at 1.82% [2]. - Over the last five trading days, the top gainers were: - Envision Biotech-B (09606) with a 6.82% increase [3]. - JinkoSolar (06680) with a 6.56% increase [3]. - Huaxin Cement (06655) with a 3.34% increase [3]. Decrease in Holdings - The companies with the largest decreases in Hong Kong Stock Connect holdings include: - Ocean Park (02255) with a decrease of 6.13%, now holding 9.89% [2]. - Da Zhong Public Utilities (01635) with a decrease of 1.00%, now at 65.40% [2]. - China Duty Free Group (01880) with a decrease of 0.82%, now at 39.15% [2]. - Over the last five trading days, the top losers were: - Ocean Park (02255) with a 5.49% decrease [3]. - Changfei Optical Fiber (06869) with a 5.13% decrease [3]. - Jiangxi Copper (00358) with a 2.40% decrease [3]. Long-term Trends - Over the last 20 days, the companies with the largest increases in holdings included: - Canggang Railway (02169) with a 31.37% increase, now at 43.06% [4]. - Da Zhong Public Utilities (01635) with a 30.70% increase, now at 65.40% [4]. - The companies with the largest decreases over the same period included: - Ocean Park (02255) with a 7.66% decrease, now at 9.89% [4]. - Longpan Technology (02465) with a 5.43% decrease, now at 46.16% [4].

Core Insights - The top three companies by Hong Kong Stock Connect holding ratios are China Telecom (00728) at 70.93%, COSCO Shipping Energy (01138) at 69.85%, and GCL-Poly Energy (01330) at 69.62% [1] Hong Kong Stock Connect Latest Holding Ratios (Top 20) - China Telecom (00728): 9.844 billion shares, 70.93% holding ratio [1] - COSCO Shipping Energy (01138): 905 million shares, 69.85% holding ratio [1] - GCL-Poly Energy (01330): 282 million shares, 69.62% holding ratio [1] - China Shenhua Energy (01088): 2.286 billion shares, 67.66% holding ratio [1] - Kaisa Group Holdings (01108): 169 million shares, 67.41% holding ratio [1] - Other notable companies include: - China Southern Power Grid (03033): 6.028 billion shares, 60.28% holding ratio [1] - GAC Group (02238): 1.629 billion shares, 57.89% holding ratio [1] Recent 5-Day Increase in Holdings (Top 10) - Xiaomi Group-W (01810): +2.213 billion CNY, +46.943 million shares [1] - InnoCare Pharma-B (09606): +1.901 billion CNY, +5.590 million shares [1] - Meituan-W (03690): +1.430 billion CNY, +14.791 million shares [1] - Other companies with significant increases include: - Pop Mart International (09992): +1.386 billion CNY [1] - China Mobile (00941): +1.383 billion CNY [1] Recent 5-Day Decrease in Holdings (Top 10) - Tracker Fund of Hong Kong (02800): -5.916 billion CNY, -22.309 million shares [1] - SMIC (00981): -1.859 billion CNY, -2.588 million shares [1] - Hang Seng China Enterprises Index (02828): -1.745 billion CNY, -1.855 million shares [1] - Other companies with notable decreases include: - Innovent Biologics (01801): -1.124 billion CNY [1] - Jiangxi Copper (00358): -0.708 billion CNY [1]

Core Viewpoint - The article discusses the recent developments and future prospects of Ying'en Biotech, highlighting its position in the ADC (Antibody-Drug Conjugate) market and the broader trends in the Chinese biotech industry, emphasizing the importance of business development (BD) and the potential for global competitiveness in the sector [1][8]. Company Overview - Ying'en Biotech was listed on the Hong Kong Stock Exchange and achieved a significant market capitalization of HKD 29.932 billion, with its stock price reaching a historical high of HKD 563.500 per share [1]. - The company has a strong focus on ADCs, with 10 clinical-stage pipelines, and is recognized as a "dark horse" in the ADC sector [2][4]. Clinical Development - The company's lead product, DB-1303, has shown significant advantages over the established drug T-DM1 in its Phase III clinical trials, indicating a promising path toward market approval [2][3]. - DB-1303 has received breakthrough therapy designation from both the FDA and CDE, showcasing its potential in treating endometrial cancer, a less competitive indication [3]. Business Development Strategy - Ying'en Biotech has successfully engaged in multiple BD transactions, partnering with notable companies such as BioNTech and GSK, which has positioned it favorably within the industry [7][8]. - The company has a strategic focus on global markets, leveraging its international team and experience to enhance its product development and commercialization efforts [6][7]. Market Trends - The ADC market is projected to grow at a compound annual growth rate (CAGR) of 34% from 2020 to 2024, with the market size expected to exceed USD 13 billion by 2024 [6]. - The article notes a shift in investor sentiment towards Chinese biotech, with a significant increase in BD transactions involving multinational corporations [8][9]. Financial Performance - Despite substantial R&D investments, Ying'en Biotech reported net losses of CNY 387 million, CNY 358 million, and CNY 1.05 billion for the years 2022 to 2024, with a loss of CNY 2.074 billion in the first half of 2025 [12]. - The company maintains confidence in its financial strategy, anticipating that its BD activities will generate significant milestone payments in the coming years [10][12]. Future Outlook - The CEO envisions a future where Chinese ADC companies will be globally recognized for their contributions to patient care, emphasizing the importance of innovation and effective clinical execution [11][12]. - Ying'en Biotech aims to transition from a biotech firm to a pharmaceutical company, focusing on maintaining its R&D integrity while expanding its global presence [10][11].

Core Viewpoint - The company, Innovent Biologics-B (09606.HK), is initiating a dual capital market strategy by planning to issue RMB ordinary shares and list on the Shanghai Stock Exchange's Sci-Tech Innovation Board, marking a significant move in its capital market activities [1][2]. Group 1: Capital Market Actions - Innovent Biologics-B's stock price rose over 5% on October 20, closing up 1.74% at 340 HKD, with a market capitalization nearing 30 billion HKD following the announcement of its plan to list on the Sci-Tech Innovation Board [2]. - The company went public on the Hong Kong Stock Exchange on April 15, raising over 1.5 billion HKD, making it one of the largest IPOs in the Hong Kong 18A sector in the past four years [2]. - The stock price peaked at 563.5 HKD in September, representing an increase of nearly 5 times from its IPO price of 94.6 HKD [2]. Group 2: Financial Performance - For the six months ending June 30, 2025, Innovent Biologics-B reported a revenue of 1.229 billion RMB, reflecting a year-on-year growth of 22.9%, primarily driven by external licensing and collaboration agreements [3]. - The company has a cash reserve of 3.75 billion RMB, sufficient to support its R&D activities for the next 3 to 5 years [3]. - Innovent Biologics-B is collaborating with BioNTech to advance its "ADC+IO" strategy, with several ADCs entering clinical trials [3]. Group 3: Strategic Focus - The company is dedicated to developing next-generation ADC innovative drugs for cancer and autoimmune diseases, with significant progress in pipeline development and business operations since early 2025 [3]. - Innovent Biologics-B aims to accelerate the global development and commercialization of its clinical projects to unlock their commercial value [3]. - The company plans to enhance its expertise in global research, clinical development, and regulatory affairs to drive future ADC innovations [3].

Core Insights - The company, Ying'en Biotech, announced plans to issue ordinary shares for listing on the Shanghai Stock Exchange's Sci-Tech Innovation Board, subject to market conditions and necessary approvals [2] Company Overview - Ying'en Biotech focuses on developing next-generation antibody-drug conjugates (ADCs) for cancer and autoimmune disease patients, aiming to innovate cancer treatment methods [2] - The company was officially listed on the Hong Kong Stock Exchange on April 15, raising approximately HKD 1.64 billion (around USD 211 million) and attracting 15 cornerstone investors, marking the largest financing scale for a Hong Kong 18A listing since 2022 [2] Financial Performance - Projected revenues for Ying'en Biotech from 2022 to 2024 are as follows: CNY 1.6 million, CNY 1.787 billion, and CNY 1.941 billion, primarily from upfront payments and milestone revenues from products like DB-1303 and DB-1311 [2] - The net profit projections for the same period are: CNY -387 million, CNY -358 million, and CNY -1.05 billion [2] - In the first half of 2025, the company reported revenue of CNY 1.229 billion, a year-on-year increase of 22.9%, while net losses expanded to CNY -2.074 billion [2]

Core Viewpoint - The trend of companies moving from Hong Kong to the A-share market is emerging, with Ying'en Biotechnology (9606.HK) planning to list on the Sci-Tech Innovation Board, marking a significant reverse operation in the current market context [1][2]. Group 1: Company Overview - Ying'en Biotechnology is a biopharmaceutical company that has not yet received approval for any drugs, primarily generating revenue through a "License-out" model, which involves licensing its candidate drugs for upfront payments, milestone payments, and sales shares [2]. - Despite generating revenue of 1.227 billion yuan through licensing deals with pharmaceutical companies like GSK in the first half of 2025, Ying'en Biotechnology remains in a loss position, reporting a net loss of 292 million yuan, which has increased over six times year-on-year [2]. Group 2: Market Context - The A-share IPO market is recovering, leading to expectations that more Hong Kong-listed companies may initiate their return to the A-share market [2]. - Other biopharmaceutical companies planning to list on the Sci-Tech Innovation Board this year are showing signs of profitability, contrasting with Ying'en Biotechnology's current financial struggles [2]. Group 3: Financial Position - Ying'en Biotechnology raised nearly 1.8 billion yuan when it listed on the Hong Kong Stock Exchange in April 2023, which has provided funding for its research and development [3]. - As of June 30, 2025, the company had cash and cash equivalents nearing 3 billion yuan, indicating a relatively strong liquidity position [4]. Group 4: Future Outlook - The necessity for further financing by Ying'en Biotechnology is being questioned, given its current cash reserves and the challenges it faces in gaining market recognition for its Sci-Tech Innovation Board IPO plan [5].

Core Viewpoint - The company, Innovent Biologics-B (09606), is planning to list on the STAR Market, pending market conditions and necessary approvals, following a successful IPO on the Hong Kong Stock Exchange that raised over HKD 1.5 billion [1] Group 1: Company Developments - Innovent Biologics' stock price increased by 5% in early trading and is currently up 3.41%, trading at HKD 345.6 with a transaction volume of HKD 599 million [1] - The company announced its intention to submit a listing application for DB-1303 (HER2ADC) for endometrial cancer in the U.S. and for breast cancer in China by 2025 [1] - The company is exploring the combination of DB-1305 (TROP2ADC) and bispecific antibodies, leading in global advancements in this area [1] Group 2: Market Insights - According to a report by CICC, the global ADC market is projected to grow from approximately USD 10.4 billion in 2023 to USD 115.1 billion by 2032 [1] - Innovent Biologics' stock price reached a peak of HKD 563.5 in September, marking a maximum increase of 495.67% from its IPO price of HKD 94.6 per share [1] - The company’s DB-1311 (B7-H3ADC) shows potential as a best-in-class treatment for prostate cancer, while DB-1310 (HER3ADC) is expected to follow suit [1]

Core Viewpoint - InnoCare Pharma-B (09606) is planning to list on the STAR Market, pending market conditions and further approvals from the board and shareholders, following a successful IPO on the Hong Kong Stock Exchange that raised over HKD 1.5 billion [1] Group 1: Company Developments - InnoCare Pharma's stock price increased by 5% in early trading, reaching HKD 345.6 with a trading volume of HKD 599 million [1] - The company was listed on the Hong Kong Stock Exchange on April 15, raising over HKD 1.5 billion, marking it as one of the largest IPOs in the Hong Kong 18A sector in the past four years [1] - The stock price peaked at HKD 563.5 in September, reflecting a maximum increase of 495.67% from the IPO price of HKD 94.6 per share [1] Group 2: Industry Insights - According to a report by CICC, the global ADC market is projected to reach approximately USD 10.4 billion in 2023 and is expected to grow to USD 115.1 billion by 2032 [1] - InnoCare Pharma plans to submit applications for its DB-1303 (HER2 ADC) for endometrial cancer in the U.S. and for breast cancer in China by 2025 [1] - The company’s DB-1311 (B7-H3 ADC) shows potential as a best-in-class candidate for prostate cancer, while DB-1310 (HER3 ADC) is expected to follow suit; DB-1305 (TROP2 ADC) and dual antibody explorations are leading globally in next-generation ADC research [1]

Core Insights - The report highlights the changes in the Hong Kong Stock Connect holdings, indicating significant increases and decreases in ownership percentages for various companies [1][2]. Group 1: Increased Holdings - The companies with the largest increases in Hong Kong Stock Connect holdings include: - Ying En Bio-B (09606) with an increase of 3.48%, bringing the total holding to 12.00% [1] - Sanhua Intelligent Control (02050) with an increase of 1.68%, totaling 13.67% [1] - Anjoy Foods (02648) with an increase of 0.74%, totaling 25.90% [1] - In the last five trading days, the top three companies with the largest increases in holdings are: - Jinli Permanent Magnet (06680) with an increase of 8.03%, totaling 30.03% [2] - Ying En Bio-B (09606) with an increase of 4.60%, totaling 12.00% [2] - ZTE Corporation (00763) with an increase of 3.55%, totaling 55.04% [2] Group 2: Decreased Holdings - The companies with the largest decreases in Hong Kong Stock Connect holdings include: - Hang Seng China Enterprises (02828) with a decrease of 10.52%, bringing the total holding to 0.96% [1] - Tracker Fund of Hong Kong (02800) with a decrease of 5.76%, totaling 0.93% [1] - Longi Green Energy (06869) with a decrease of 2.05%, totaling 63.46% [1] - In the last five trading days, the top three companies with the largest decreases in holdings are: - Longi Green Energy (06869) with a decrease of 5.78%, totaling 63.46% [2] - Jihong Co., Ltd. (02603) with a decrease of 2.74%, totaling 34.06% [2] - Chongqing Steel (01053) with a decrease of 2.18%, totaling 27.24% [2] Group 3: Long-term Trends - Over the last 20 days, the companies with the largest increases in holdings include: - Dazhong Public Utilities (01635) with an increase of 33.41%, totaling 66.40% [2] - Canggang Railway (02169) with an increase of 31.40%, totaling 43.06% [2] - Shankou Holdings (00412) with an increase of 15.66%, totaling 17.10% [2] - The companies with the largest decreases in holdings over the last 20 days include: - Hang Seng China Enterprises (02828) with a decrease of 5.89%, bringing the total holding to 0.96% [4] - Baiguoyuan Group (02411) with a decrease of 4.60%, totaling 6.81% [4] - Huizhong Network (09878) with a decrease of 4.11%, totaling 21.70% [4]